Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:sodium-glucose transport protein subtype 2 inhibitor
go back to main search page
Accession:CHEBI:73273 term browser browse the term
Definition:An inhibitor that interferes with the action of sodium-glucose transport protein subtype 2.
Synonyms:related_synonym: SGLT2 inhibitor;   SGLT2 inhibitors;   sodium glucose co-transporter 2 inhibitor;   sodium glucose co-transporter 2 inhibitors;   sodium-glucose transport protein subtype 2 inhibitors
 xref: Wikipedia:SLC5A2


show annotations for term's descendants           Sort by:
 
canagliflozin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ache acetylcholinesterase multiple interactions EXP Canagliflozin inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased activity of ACHE protein]; Canagliflozin inhibits the reaction [Scopolamine results in increased activity of ACHE protein] CTD PMID:27566243, PMID:28837785 NCBI chr12:22,472,358...22,477,052
Ensembl chr12:22,472,358...22,478,753
JBrowse link
G Chrm1 cholinergic receptor, muscarinic 1 decreases expression
multiple interactions
EXP Canagliflozin results in decreased expression of CHRM1 protein
Canagliflozin affects the reaction [Scopolamine results in decreased expression of CHRM1 protein]
CTD PMID:28837785 NCBI chr 1:224,869,087...224,885,101
Ensembl chr 1:224,882,439...224,884,205
JBrowse link
G Havcr1 hepatitis A virus cellular receptor 1 increases expression EXP Canagliflozin results in increased expression of HAVCR1 CTD PMID:25130857 NCBI chr10:31,813,819...31,860,934
Ensembl chr10:31,813,814...31,848,379
JBrowse link
G Lhb luteinizing hormone subunit beta increases expression EXP Canagliflozin results in increased expression of LHB protein CTD PMID:25289773 NCBI chr 1:101,409,992...101,413,725
Ensembl chr 1:101,410,019...101,413,724
JBrowse link
G Pth parathyroid hormone decreases expression EXP Canagliflozin results in decreased expression of PTH protein CTD PMID:25289773 NCBI chr 1:178,215,829...178,218,761
Ensembl chr 1:178,215,829...178,218,761
JBrowse link
G Slc5a2 solute carrier family 5 member 2 decreases activity ISO Canagliflozin results in decreased activity of SLC5A2 protein CTD PMID:21128592 NCBI chr 1:199,682,688...199,688,809
Ensembl chr 1:199,682,688...199,688,809
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19785
    role 19732
      biological role 19732
        biochemical role 19281
          sodium-glucose transport protein subtype 2 inhibitor 6
            Synjardy 0
            canagliflozin + 6
            canagliflozin hydrate 0
            dapagliflozin + 0
            dapagliflozin propanediol monohydrate 0
            empagliflozin + 0
paths to the root

NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.